Given that LMs often are caused by some of the same mutations in the PI3K/AKT/mTOR and RAS/MAPK pathways that promote cancer, several drugs already approved for cancer treatment can be repurposed for patients with LM, thus shortening the clinical approval process. This evidence concerns the gene PIK3CD and cancer.